Fuming Zi

778 total citations
21 papers, 600 citations indexed

About

Fuming Zi is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Fuming Zi has authored 21 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Fuming Zi's work include Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Protein Degradation and Inhibitors (3 papers). Fuming Zi is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Protein Degradation and Inhibitors (3 papers). Fuming Zi collaborates with scholars based in China, United States and Slovenia. Fuming Zi's co-authors include Zhen Cai, Jingsong He, Yi Li, Donghua He, Jing Cheng, Yang Li, Yi Li, Li Yang, Li Yu and Yi Zhao and has published in prestigious journals such as Molecular and Cellular Biology, Scientific Reports and Cancer Letters.

In The Last Decade

Fuming Zi

21 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fuming Zi China	15	310	286	156	85	82	21	600
Stephany Corrêa Brazil	13	432 1.4×	209 0.7×	209 1.3×	76 0.9×	50 0.6×	27	670
Jia Gu China	12	184 0.6×	116 0.4×	136 0.9×	99 1.2×	63 0.8×	33	428
Kimie Kondo United States	15	484 1.6×	259 0.9×	127 0.8×	39 0.5×	149 1.8×	22	793
Mi Kwon Son South Korea	18	418 1.3×	302 1.1×	132 0.8×	65 0.8×	34 0.4×	41	830
Yanling Sun China	13	348 1.1×	124 0.4×	155 1.0×	132 1.6×	51 0.6×	52	580
Sylvie Shen Australia	14	447 1.4×	202 0.7×	177 1.1×	123 1.4×	85 1.0×	26	840
Kinga A. Kocemba‐Pilarczyk Poland	11	390 1.3×	170 0.6×	156 1.0×	58 0.7×	143 1.7×	24	570
Sandra Jensen-Taubman United States	12	311 1.0×	252 0.9×	228 1.5×	87 1.0×	28 0.3×	17	596
Vanessa S. Silveira Brazil	16	430 1.4×	117 0.4×	102 0.7×	45 0.5×	98 1.2×	32	648

Countries citing papers authored by Fuming Zi

Since Specialization

Citations

This map shows the geographic impact of Fuming Zi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuming Zi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuming Zi more than expected).

Fields of papers citing papers by Fuming Zi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fuming Zi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuming Zi. The network helps show where Fuming Zi may publish in the future.

Co-authorship network of co-authors of Fuming Zi

This figure shows the co-authorship network connecting the top 25 collaborators of Fuming Zi. A scholar is included among the top collaborators of Fuming Zi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fuming Zi. Fuming Zi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zi, Fuming, et al.. (2024). lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts. International Immunopharmacology. 142(Pt B). 113080–113080. 1 indexed citations

Ding, Qiang, et al.. (2023). A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors. Frontiers in Oncology. 13. 1049147–1049147. 5 indexed citations

Zi, Fuming, et al.. (2023). Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis. International Immunopharmacology. 119. 110058–110058. 5 indexed citations

Zi, Fuming, et al.. (2023). The novel HLA‐C*03:621 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual. HLA. 102(1). 91–92. 1 indexed citations

Li, Ruiqi, et al.. (2022). A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors. Scientific Reports. 12(1). 18807–18807. 20 indexed citations

Wang, Qingming, Wenfeng He, Yan Huang, et al.. (2021). A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cellular Immunology. 363. 104342–104342. 18 indexed citations

Zi, Fuming, et al.. (2021). Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. Medicine. 100(19). e25786–e25786. 26 indexed citations

Zhang, Yuan, et al.. (2020). Expression and role of fibroblast activation protein α in acute myeloid leukemia. Oncology Reports. 45(2). 641–651. 6 indexed citations

Fu, Xiao, et al.. (2019). The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. International Immunopharmacology. 73. 181–192. 33 indexed citations

10.

Zi, Fuming, et al.. (2019). Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p. Molecular and Cellular Biology. 40(3). 40 indexed citations

11.

Zi, Fuming, et al.. (2019). Ibrutinib in CLL/SLL: From bench to bedside (Review). Oncology Reports. 42(6). 2213–2227. 16 indexed citations

12.

Yan, Haimeng, Donghua He, Xi Huang, et al.. (2018). Role of interleukin‑32 in cancer biology (Review). Oncology Letters. 16(1). 41–47. 17 indexed citations

13.

Zi, Fuming, et al.. (2018). I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma. Bioscience Reports. 39(5). 16 indexed citations

14.

Cheng, Jing, et al.. (2017). I-BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages. Molecular Medicine Reports. 16(6). 8406–8412. 2 indexed citations

15.

Yang, Li, Gang Wang, Fuming Zi, et al.. (2017). Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget. 8(54). 92841–92854. 23 indexed citations

16.

He, Donghua, Xing Guo, Enfan Zhang, et al.. (2016). Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models. Oncotarget. 7(29). 45489–45499. 30 indexed citations

17.

Zi, Fuming, Jingsong He, Donghua He, et al.. (2015). Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review). Molecular Medicine Reports. 11(5). 3203–3211. 107 indexed citations

18.

Zi, Fuming, Yi Li, Cai Wu, et al.. (2014). Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biology & Therapy. 15(10). 1413–1422. 22 indexed citations

19.

Zi, Fuming, Yi Li, Cai Wu, et al.. (2014). Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Letters. 356(2). 443–453. 50 indexed citations

20.

Zhao, Yi, Qiuyan Liu, Yang Li, et al.. (2012). TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Cellular and Molecular Immunology. 10(2). 165–175. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact